Oncology

Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan in Lung and Breast Cancer

TOKYO & BASKING RIDGE, N.J. & MUNICH & VILLEJUIF, France–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Gustave Roussy today announced a multi-year, multi-study research collaboration to enrich and further enable the development of DS-1062 and patritumab deruxtecan (U3-1402), two of Daiichi Sankyo’s lead DXd antibody drug conjugates (ADCs), …

Read More »

Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with Keytruda in NSCLC

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating Fields together with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treatment of non-small cell lung cancer (NSCLC). Novocure’s …

Read More »

FDA Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for GSK’s Belantamab mafodotin for Relapsed/Refractory Multiple Myeloma

  LONDON, July 14, 2020 /PRNewswire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients with relapsed or refractory multiple myeloma …

Read More »

Blueprint Medicines Collaborates with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers

CAMBRIDGE, Mass., July 14, 2020 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it has entered into a global collaboration with Roche and Genentech, a member of the Roche Group, to develop and commercialize …

Read More »

Genentech’s Tecentriq Fails to Meet Primary Endpoint in Phase 3 Study in Women with Advanced-Stage Ovarian Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of …

Read More »

FDA Grants Priority Review to Merck’s sBLA for Second-Line Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult …

Read More »

HPV Test Misses Twice as Many Women Who Develop Cervical Cancer as Cotesting, Quest Diagnostics Health Trends Study Finds

SECAUCUS, N.J., July 8, 2020 /PRNewswire/ — A Health Trends™ study from researchers at Quest Diagnostics (NYSE: DGX) and the University of Pittsburgh Medical Center (UPMC) provides new evidence that the HPV screening test is significantly less likely to detect cervical cancer and precancer than cotesting, a method which combines …

Read More »

Xencor and Atreca Partner to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on …

Read More »

Merck and Foghorn Collaborate to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foghorn® Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in oncology, announced that it has entered into a strategic collaboration with Merck, known as MSD outside the United States and Canada. The collaboration will apply Foghorn’s proprietary Gene Traffic Control™ product platform …

Read More »

Merck and Eisai Receive CRL from the FDA for Keytruda Plus Lenvima Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s and Eisai’s applications seeking accelerated approval of KEYTRUDA, Merck’s anti-PD-1 therapy, …

Read More »